Literature DB >> 16265534

Therapy insight: cardiovascular complications associated with muscular dystrophies.

Elizabeth M McNally1, Heather MacLeod.   

Abstract

The muscular dystrophies are commonly associated with cardiovascular complications, including cardiomyopathy and cardiac arrhythmias. These complications are caused by intrinsic defects in cardiomyocyte and cardiac conduction system function, and by the presence of severe skeletal muscle disease, which also contributes to cardiac dysfunction. Unlike the skeletal muscle degenerative process, for which treatment options are currently limited, therapy is available for the cardiovascular complications that accompany muscular dystrophy. New therapies for skeletal muscle degeneration are moving into clinical trials and, ultimately, into clinical practice. These therapies are expected to also improve the cardiac function, longevity and wellbeing of muscular dystrophy patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265534     DOI: 10.1038/ncpcardio0213

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  8 in total

Review 1.  Mechano-chemo-transduction in cardiac myocytes.

Authors:  Ye Chen-Izu; Leighton T Izu
Journal:  J Physiol       Date:  2017-03-10       Impact factor: 5.182

2.  Phenotyping cardiac gene therapy in mice.

Authors:  Brian Bostick; Yongping Yue; Dongsheng Duan
Journal:  Methods Mol Biol       Date:  2011

3.  Exacerbation of dystrophic cardiomyopathy by phospholamban deficiency mediated chronically increased cardiac Ca2+ cycling in vivo.

Authors:  Michelle L Law; Kurt W Prins; Megan E Olander; Joseph M Metzger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-17       Impact factor: 4.733

4.  Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart.

Authors:  Xaver Koenig; Sandra Dysek; Stefanie Kimbacher; Agnes K Mike; Rene Cervenka; Peter Lukacs; Katrin Nagl; Xuan B Dang; Hannes Todt; Reginald E Bittner; Karlheinz Hilber
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

Review 5.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Miranda D Grounds; Hannah G Radley; Gordon S Lynch; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  Neurobiol Dis       Date:  2008-04-09       Impact factor: 5.996

Review 6.  Voltage-Dependent Sarcolemmal Ion Channel Abnormalities in the Dystrophin-Deficient Heart.

Authors:  Xaver Koenig; Janine Ebner; Karlheinz Hilber
Journal:  Int J Mol Sci       Date:  2018-10-23       Impact factor: 6.208

7.  Next-generation muscle-directed gene therapy by in silico vector design.

Authors:  S Sarcar; W Tulalamba; M Y Rincon; J Tipanee; H Q Pham; H Evens; D Boon; E Samara-Kuko; M Keyaerts; M Loperfido; E Berardi; S Jarmin; P In't Veld; G Dickson; T Lahoutte; M Sampaolesi; P De Bleser; T VandenDriessche; M K Chuah
Journal:  Nat Commun       Date:  2019-01-30       Impact factor: 14.919

Review 8.  Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability.

Authors:  Mbarka Bchetnia; Luigi Bouchard; Jean Mathieu; Philippe M Campeau; Charles Morin; Diane Brisson; Anne-Marie Laberge; Hélène Vézina; Daniel Gaudet; Catherine Laprise
Journal:  J Med Genet       Date:  2021-04-28       Impact factor: 6.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.